2. Stem Cell/Wnt Cell Cycle/DNA Damage
  3. Wnt β-catenin CDK
  4. KY19334

KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes.

For research use only. We do not sell to patients.

KY19334

KY19334 Chemical Structure

CAS No. : 2319609-67-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

KY19334 Related Antibodies

Top Publications Citing Use of Products

View All Wnt Isoform Specific Products:

View All Isoforms
Wnt1 Wnt3 Wnt5 Wnt7

View All CDK Isoform Specific Products:

View All Isoforms
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes[1].

IC50 & Target[1]

CDK1

 

In Vitro

KY19334 (5 μM, 72 h) inhibits the proliferation of human cutaneous squamous cell carcinoma (cSCC) cells HSC-1 and HSC-5, but exerts no significant proliferation inhibition on normal keratinocyte HaCaT cells[1].
KY19334 (5 μM, 24 h) significantly inhibits the migration and invasion of HSC-1 and HSC-5 cells[1].
KY19334 (5 μM, 2 weeks) inhibits the colony formation of HSC-1 and HSC-5 cells[1].
KY19334 (5 μM, 24 h) downregulates CDK1 expression and inhibits the Wnt/β-catenin signaling pathway in HSC-1 and HSC-5 cells[1].
KY19334 (1 mM, 7-16 days) activates the Wnt/β-catenin signaling pathway in keratinocytes, vascular endothelial cells, and fibroblasts of wound tissues from diabetic mice[2].
KY19334 (1 mM, 7 days) promotes the expression of angiogenesis-related proteins in CD31+ vascular endothelial cells of diabetic mouse wound tissues[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KY19334 Related Antibodies

Western Blot Analysis[1]

Cell Line: HSC-1 and HSC-5 cells
Concentration: 5 μM
Incubation Time: 24 h
Result: Reduced CDK1 levels by approximately 50%.
Did not alter the expression of CDK4.
Increased the phosphorylation of β-catenin at Ser33/37/Thr41.
Downregulated the expression of downstream target genes c-Myc and Cyclin D1.

ELISA Assay[2]

Cell Line: CD31+ vascular endothelial cells of diabetic mouse wound tissues
Concentration: 1 mM
Incubation Time: 7 days
Result: Increased VEGFA secretion (approximately 80%), CD31+ capillary density (approximately 75%) and VEGFR2 protein level (approximately 65%).
Downregulated the expression of anti-angiogenic factor Serpin F1 (PEDF) (approximately 50%).
In Vivo

KY19334 (2 mM, topically application, 30 mins before each TPA) significantly inhibits the development of DMBA (HY-W011845)/TPA-induced skin cancer in C57BL/6 mice[1].
KY19334 (1 mM, topically application, daily for 16 days) accelerates wound healing in diabetic C57BL/6 mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DMBA (HY-W011845)/TPA-induced skin cancer C57BL/6 mice models[1]
Dosage: 2 mM
Administration: Topically application, 30 mins before each TPA
Result: Decreased tumor numbers and average size.
Improved tumor grading.
Reduced the proportions of hyperplasia, papilloma and carcinoma in situ.
Decreased the proportion of SCC.
Downregulated the expressions of CDK1, β-catenin, c-Myc, Cyclin D1 and PCNA in tumor tissues.
Upregulated the expressions of tumor suppressor proteins p21Cip/WAF and p27.
Animal Model: HFD (high fat diet)+STZ (HY-13753)-induced diabetic C57BL/6 mice and db/db mice[2]
Dosage: 1 mM
Administration: Topically application, daily for 16 days
Result: Increased the wound closure rate.
Enhanced collagen deposition in wound tissues.
Restored the proliferation of Keratin14+ keratinocytes and CD31+ capillary density.
Increased nuclear β-catenin expression.
Molecular Weight

307.30

Formula

C17H13N3O3
CAS No.
SMILES

O=C(NC1=C/2C=C(OC)C=C1)C2=C3NC4=CC=CC=C4C/3=N\O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

KY19334 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KY193342319609-67-9KY 19334KY-19334Wntβ-cateninCDKBeta cateninCyclin dependent kinaseCXXC5DVLCDK1Cutaneous squamous cell carcinomaDiabetesHSC-1HSC-5DMBATPAInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
KY19334
Cat. No.:
HY-178227
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.